Highlights Newsletter 4
This newsletter presents you the following key sessions:
3. Pegcetacoplan superior to eculizumab in patients with paroxysmal nocturnal haemoglobinuria
- Home
- Archive
-
EHA 2022
-
IWWM 2022
-
Highlights Newsletter 1
- Podcast with Prof. Jorge Castillo about long-term follow-up of ibrutinib monotherapy in treatment-naïve Waldenström macroglobulinemia
- Podcast with Prof. Evangelos Terpos about responses to COVID vaccination in patients with plasma cell neoplasms
- Podcast with Prof. Constantine Tam about response to BTK inhibitor treatment in patients with Waldenström macroglobulinemia
- Podcast with Prof. Christian Buske about the long-term follow-up of the iNNOVATE study
-
Highlights Newsletter 2
- Podcast with Prof. Véronique Leblond about a phase II study exploring the “chemo-free” treatment association of idelalisib and obinutuzumab in relapsed or refractory WM
- Podcast with Dr. Marzia Varettoni about the first results of the BIOWM study analysing the genomic landscape of WM patients and novel screening techniques
- Podcast with Dr. Tina Bagratuni about a single-cell analysis of mutated and wildtype MYD88 WM
- Podcast with Dr. Shirley D’Sa about Real-World safety and efficacy of ibrutinib in patients with WM: The UK experience
-
Highlights Newsletter 1
-
ASH 2022
